← All claims

Metabolic & Cardiometabolic · Gut & Microbiome

oral bile acid (CDCA) increases GLP-1

In plain terms: Does an oral bile acid boost the gut hormone GLP-1 in people?

Leans support Metabolic & Cardiometabolic 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.51

Probably yes for the bile acid itself, but whether ordinary diet can do the same is unproven.

📅 Last reviewed: 2026-07-15

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Human trials (RCT / n-of-1)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

9 support 1 contradict 3 tested null 4 mixed · 17 sources, 9 independent groups

What the evidence shows

Direct chenodeoxycholic acid raises GLP-1 in humans (intragastric, and post-RYGB), but bile-acid SEQUESTRANTS do not raise GLP-1 in humans despite lowering glucose — so the human glucose benefit of sequestrants is not GLP-1-mediated. Bile acids CAN drive human GLP-1; whether diet can is unproven.

The evidence (17)

SourceGradeStanceQualityFinding
Kuhre
2018 · Mol Metab
animal supports moderate Bile acids are direct and indirect regulators of GLP-1 and other gut/pancreatic hormone secretion.
Smushkin G et al] # corrected 2026-08-17 from PubMed; was [(colesevelam RCT)
2013 · (human RCT)
RCT tested-null moderate n=38 RCT 12wk: improved glycemia but postprandial GLP-1 UNCHANGED (mechanism = glucose sequestration)
Beysen C et al] # corrected 2026-08-17 from PubMed; was [Hansen
2012 · Diabetologia
RCT supports moderate Colesevelam improved glucose metabolism with bile-acid-mediated GLP-1 mechanism in type-2 diabetes RCT.
Sun YH et al
2026 · study_type: animal
animal mixed low Mouse MASLD model: herbal decoction (LGZG) enriched endogenous non-12-OH bile acids (HCA, 7-ketoLCA), known TGR5 agonists; serum GLP-1 elevated (p<0.05) alongside adipose TGR5-cAMP/PKA/CREB activation.
Christiansen
2019 · Am J Physiol Gastrointest
animal supports moderate Bile acids drive colonic GLP-1 and PYY secretion 3.5x via basolateral TGR5 in perfused rat/mouse colon.
Roberts
2011 · Clin Endocrinol
observational supports moderate Postprandial bile acid concentrations correlate with GLP-1 and PYY secretion in humans.
Murakami
2013 · SpringerPlus
observational supports low Oral ursodeoxycholic acid with a meal raised GLP-1 secretion and lowered blood glucose in non-diabetic humans.
Lv J et al
2026 · study_type: animal
animal tested-null moderate Mouse: oral UDCA recapitulated anti-obesity/metabolic benefits of BSH-probiotic; UDCA acted as intestinal FXR antagonist + TGR5 agonist, stimulated GLP-1 secretion; HepG2 cells showed UDCA directly activates GLP-1 receptor.
Nielsen S et al] # corrected 2026-08-17 from PubMed; was [(CDCA post-RYGB)
2017 · (human crossover)
RCT supports moderate Oral CDCA raised GLP-1/PYY/FGF19 in post-RYGB (n=11); UDCA did not
Bronden
2018 · Diabetes Obes Metab
RCT mixed high Sevelamer (bile-acid sequestrant) abolished the acute endogenous-bile-acid GLP-1 stimulus in T2D-confirms bile acids drive GLP-1.
Hansen M, et al. (Knop)
2016 · (human crossover)
RCT supports moderate Intragastric CDCA increased plasma GLP-1 (human crossover)
Wu
2013 · Diabetes Obes Metab
RCT supports moderate Rectal taurocholic acid dose-dependently stimulated GLP-1 and PYY in healthy men.
Ma H et al
2026 · study_type: animal
animal mixed moderate 46 obesity-prone humans had depleted GDCA (observational only, no GLP-1 measured in humans); FMT-recipient + GDCA-supplemented mice: GDCA activated TGR5, increased ileal GLP-1 secretion and BAT thermogenesis.
Gether IM et al] # corrected 2026-08-17 from PubMed; was [(Knop, colesevelam)
2024 · (human crossover)
RCT tested-null moderate Single-dose colesevelam: no acute postprandial GLP-1 rise
She J, et al.
2024 · Cell Metab
mechanism mixed high Statin-driven bile-acid/microbiome shifts reduce GLP-1 and worsen insulin resistance-supports bile-acid-GLP-1 axis indirectly.
Brighton CA, et al.
2015 · Endocrinology
mechanism supports moderate Bile acids trigger GLP-1 release predominantly via basolateral GPBAR1/TGR5 on L-cells.
Trabelsi MS, et al.
2015 · Nat Commun
in-vitro contradicts moderate FXR activation (a bile-acid receptor) INHIBITS GLP-1 production by L-cells-bile-acid effect on GLP-1 is receptor-dependent and bidirectional.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.